1-3 of 3
Yutaka Kanda
Close
Sort by
Journal Articles

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

Yukimasa Shiotsu, Hitoshi Kiyoi, Yuichi Ishikawa, Ryohei Tanizaki, Makiko Shimizu, Hiroshi Umehara, Kenichi Ishii, Yumiko Mori, Kazutaka Ozeki, Yosuke Minami, Akihiro Abe, Hiroshi Maeda, Tadakazu Akiyama, Yutaka Kanda, Yuko Sato, Shiro Akinaga, Tomoki Naoe
Journal: Blood
Blood (2009) 114 (8): 1607–1617.
https://doi.org/10.1182/blood-2009-01-199307
Published: 2009
Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Ryohei Tanizaki, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Yuichi Ishikawa, MD, PhD, Kenichi Ishii, Makiko Shimizu, Yutaka Kanda, PhD, Yuko Sato, MD, PhD, Shiro Akinaga, PhD, Jorge Cortes, MD, Tomoki Naoe, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1640.
https://doi.org/10.1182/blood.V112.11.1640.1640
Published: 2008
Journal Articles

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Juliger, Takayuki Nakashima, Lenushka Maharaj, Toshihiko Ishii, Hiroshi Nakagawa, Yutaka Kanda, Heather Oakervee, James Cavenagh, Shiro Akinaga, Yukimasa Shiotsu, Simon P Joel
Journal: Blood
Blood (2008) 112 (11): 1625.
https://doi.org/10.1182/blood.V112.11.1625.1625
Published: 2008